Chat with us, powered by LiveChat

Loading...

Therapeutic Obstructive Sleep Apnea Device Market

RA00039

Therapeutic Obstructive Sleep Apnea Device Market by Type (Airway clearance systems, Adaptive servo-ventilation (ASV), Positive airway pressure (PAP) device, Oral appliances, Oxygen devices, and Others), By End use (Hospitals & Sleep Laboratories, Home Care Settings), Regional Outlook (North America, Europe, Asia-Pacific, LAMEA), Global Opportunity Analysis and Industry Forecast, 2019–2026

RA00039

Pages: 110

Jan 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Therapeutic Obstructive Sleep Apnea Device Market

Therapeutic Obstructive Sleep Apnea Device Market Outlook 2026:

Therapeutic obstructive sleep apnea device market forecasted to grow at a CAGR of 9.6% generating a revenue of $9,561.3 million by 2026 from $4661.6 million in 2018.

Obstructive sleep apnea is a sleeping disorder where the breathing starts and stops simultaneously during sleep. Therapeutic obstructive sleep apnea occurs when the throat muscles lessen and blocks the air way while sleeping. Snoring is the most noticeable sign of obstructive sleep apnea. This type of problem is mostly encountered in the patient facing with neurological disorder.

The most common symptoms like excessive daytime sleepiness, snoring, non-refreshing sleep, and chocking are related to the obstructive sleep apnea. It is being predicted that 9-26% of middle aged population are experiencing obstructive sleep apnea more than 15 times in an hour.

Therapeutic obstructive sleep apnea device market drivers:

Rising cases of undiagnosed patient and rising awareness in the therapeutic obstructive sleep apnea is anticipated to boost the growth of therapeutic obstructive sleep apnea device market.

It has been predicted that approximately 80% of people who are facing obstructive sleep apnea are undiagnosed. If obstructive sleep apnea is left untreated, it may further cause various health issues such as diabetes, high blood pressure and sometimes it may even cause to death. The rising sleep apnea cases is the key factor for the growth of therapeutic obstructive sleep apnea devices in the near future. The growing cases of sleep apnea and the treatment followed by patient is very less, so spreading awareness among the patient about the sleep apnea devices can be considered as one of the main driving factor for therapeutic obstructive sleep apnea devices. Government initiative and the technology advancement in the device is also expected to drive the market for the therapeutic obstructive sleep apnea devices.

Market Restraints:

The high cost of the sleep apnea devices and patient being claustrophobic using devices are the major threats for the growth of Therapeutic obstructive sleep apnea devices.

The biggest restraints in the therapeutic obstructive sleep apnea device market are, the patients are not accepting the device which consist of mask which causes discomfort to the patient as the pipe is attached to the mask and the mask is being completely covered which make patient claustrophobic regarding the devices. The high cost of the sleep apnea devices can be considered as one of the biggest restraint for the growth of the therapeutic obstructive sleep apnea devices. Due to fear and high cost, lack of intrest from customers for these devices is anticipated to hamper the growth of therapeutic obstructive sleep apnea device market.

Therapeutic obstructive sleep apnea device market, by Type Segment:

Positive airway pressure is predicted to be most profitable till the end of 2026

Therapeutic obstructive sleep apnea device market, by Type Segment

Source: Research Dive Analysis

Based on the type the therapeutic obstructive sleep apnea device market is segmented into Airway clearance systems, Adaptive servo-ventilation (ASV), Positive airway pressure (PAP) device, Oral appliances, Oxygen devices, and Others. Positive airway pressure segment experienced a significant growth in the year 2018 accounting for $2,569.39, and is further projected to grow to reach $5,218.43 million in 2026. Positive airway pressure eradicates the nighttime apnea event and prevent the collapse of the airways are the major factors which helps to grow in the obstructive sleep apnea device. The Oral Products market is projected to have the highest CAGR of 9.7% over the forecast period, as these devices are available at a lower prices and provide better patient satisfaction, and better adherence to diagnosis due to its small size.

Therapeutic obstructive sleep apnea device market, by End use

Sleep laboratories and hospital will possess high investment opportunities in the coming future.

Therapeutic obstructive sleep apnea device market, by End use

Source: Research Dive Analysis

Based on the end use the therapeutic obstructive sleep apnea device market is segmented into hospitals & sleep laboratories, home care settings. Hospital and Sleep laboratories are expected to have a significant growth which generated a revenue of $ 2,569.39 million in 2018, and is further projected to grow with $ 5,218.43 million in 2026. Due to the increasing number of clinics, rising health care expenditure, safety for the patient is expected to boost to hospital and sleep laboratories segment.

Regional Growth of Therapeutic obstructive sleep apnea device market

North America region will have enormous opportunities for the market investors to grow over the coming years

Regional Growth of Therapeutic obstructive sleep apnea devices market

Source: Research Dive Analysis

North America's regional market held the largest therapeutic obstructive sleep apnea devices share in 2018.
North America regional market held the market size of $1,850.6 million in 2018 and is expected to reach $ 3,970.7 million by 2026, at a CAGR of 10.2%. Increasing cases of sleep apnea and rising geriatric population in this region is considered to be the largest market for therapeutic obstructive sleep apnea devices.

Asia Pacific Therapeutic Obstructive Sleep Apnea Device Market:
Asia-Pacific is considered to be one of the emerging market for the therapeutic obstructive sleep apnea devices, which accounted for $ 904.3 million in 2018, and is further projected to grow $ 1,777.7 million in 2026. As most parts of the Asia-Pacific remain undiagnosed and lack of awareness about the apnea device are the key growth factors that will drive the region for the Asia-Pacific region in the forecast period.

Key participants in Global Therapeutic obstructive sleep apnea devices:

Product development and joint ventures are the most common strategies followed by the market players

Key participants in Global Cancer Stem Cells Market

Source: Research Dive Analysis

Key companies operating in the therapeutic obstructive sleep apnea devices are BMC Medical Co., Ltd, Becton Dickinson (CareFusion Corporation). Braebon Medical Corporation, Cadwell Laboratories Inc., Compumedics Limited, Curative Medical Inc., Fisher & Paykel Healthcare, GE Healthcare, ImThera Medical, Inc., Invacare Corporation, therapeutic obstructive sleep apnea device market development includes mergers & acquisitions, joint ventures and product launches.

Scope of the Market Report:

   Aspect

Particulars

   Historical Market Estimations

   2016-2018

   Base Year for Market Estimation

   2018

   Forecast timeline for Market Projection

   2019-2026

   Geographical Scope

   North America, Europe, Asia-Pacific, LAMEA

   Segmentation by Type

  • Airway clearance systems
  • Adaptive servo-ventilation (ASV)
  • Positive airway pressure (PAP) device
  • Oral appliances
  • Oxygen devices
  • Others

   Segmentation by end use

  • Hospitals & Sleep Laboratories
  • Home Care Settings

   Key Countries covered

U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia

   Key Companies Profiled

  • BMC Medical Co., Ltd
  • Becton Dickinson (CareFusion Corporation).
  • Braebon Medical Corporation
  • Cadwell Laboratories Inc.
  • Compumedics Limited
  • Curative Medical Inc
  • Fisher & Paykel Healthcare
  • GE Healthcare
  • ImThera Medical, Inc.
  • Invacare Corporation

Source: Research Dive Analysis


FREQUENTLY ASKED QUESTIONS?
 

A. The global therapeutic obstructive sleep apnea devices market size was over $4,661.60 Million in 2018, and is further anticipated to reach $9,561.33 million by 2026.

A. GE Healthcare are some of the key players in the global therapeutic obstructive sleep apnea devices market.

A. North America possess great investment opportunities for the investors to witness the most promising growth in the coming years.

A. North America therapeutic obstructive sleep apnea devices market is projected to grow at 10.2% CAGR during the forecast period.

A. Product development, and joint ventures are the key strategies opted by the operating companies in this market.

A. GE Healthcare, BMC Medical Co., Ltd and Becton Dickinson are the companies investing more on R&D activities for developing new products and technologies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters

1.4.1. Assumptions
1.4.2. Forecast parameters

1.5. Data sources

1.5.1. Primary
1.5.2. Secondary

2. Executive Summary

2.1. 360° summary
2.2. Type trends
2.3. End-use trends

3. Market overview

3.1. Market segmentation & definitions
3.2. Key takeaways

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market

3.4. Market dynamics

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities

3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Pricing overview

3.8.1. By type
3.8.2. By end-use
3.8.3. By region

3.9. Market value chain analysis

3.9.1. Stress point analysis
3.9.2. Raw material analysis
3.9.3. Manufacturing process
3.9.4. Distribution channel analysis
3.9.5. Operating vendors

3.9.5.1. Raw material suppliers
3.9.5.2. Product manufacturers
3.9.5.3. Product distributors

3.10. Strategic overview

4. Therapeutic Obstructive Sleep Apnea Devices Market, by Type

4.1. Airway clearance systems

4.1.1. Market size and forecast, by region, 2017-2028
4.1.2. Comparative market share analysis, 2018 & 2028

4.2. Adaptive servo-ventilation (ASV)

4.2.1. Market size and forecast, by region, 2017-2028
4.2.2. Comparative market share analysis, 2018 & 2028

4.3. Positive airway pressure

4.3.1. Market size and forecast, by region, 2017-2028
4.3.2. Comparative market share analysis, 2018 & 2028

4.4. Oral appliances

4.4.1. Market size and forecast, by region, 2017-2028
4.4.2. Comparative market share analysis, 2018 & 2028

4.5. Oxygen devices

4.5.1. Market size and forecast, by region, 2017-2028
4.5.2. Comparative market share analysis, 2018 & 2028

4.6. Others

4.6.1. Market size and forecast, by region, 2017-2028
4.6.2. Comparative market share analysis, 2018 & 2028

5. Therapeutic Obstructive Sleep Apnea Devices Market, by End-use

5.1. Hospitals & Sleep Laboratories

5.1.1. Market size and forecast, by region, 2017-2028
5.1.2. Comparative market share analysis, 2018 & 2028

5.2. Home Care Settings

5.2.1. Market size and forecast, by region, 2017-2028
5.2.2. Comparative market share analysis, 2018 & 2028

6. Therapeutic Obstructive Sleep Apnea Devices Market, by Region

6.1. North America

6.1.1. Market size and forecast, by type, 2016-2026
6.1.2. Market size and forecast, by end-use, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026

6.1.5. U.S.

6.1.5.1. Market size and forecast, by type, 2016-2026
6.1.5.2. Market size and forecast, by end-use, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026

6.1.6. Canada

6.1.6.1. Market size and forecast, by type, 2016-2026
6.1.6.2. Market size and forecast, by end-use, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026

6.2. Europe

6.2.1. Market size and forecast, by type, 2016-2026
6.2.2. Market size and forecast, by end-use, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026

6.2.5. Germany

6.2.5.1. Market size and forecast, by type, 2016-2026
6.2.5.2. Market size and forecast, by end-use, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026

6.2.6. France

6.2.6.1. Market size and forecast, by type, 2016-2026
6.2.6.2. Market size and forecast, by end-use, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026

6.2.7. U.K.

6.2.7.1. Market size and forecast, by type, 2016-2026
6.2.7.2. Market size and forecast, by end-use, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026

6.2.8. Italy

6.2.8.1. Market size and forecast, by type, 2016-2026
6.2.8.2. Market size and forecast, by end-use, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026

6.2.9. Spain

6.2.9.1. Market size and forecast, by type, 2016-2026
6.2.9.2. Market size and forecast, by end-use, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026

6.2.10. Russia

6.2.10.1. Market size and forecast, by type, 2016-2026
6.2.10.2. Market size and forecast, by end-use, 2016-2026
6.2.10.3. Comparative market share analysis, 2018 & 2026

6.2.11. Rest of Europe

6.2.11.1. Market size and forecast, by type, 2016-2026
6.2.11.2. Market size and forecast, by end-use, 2016-2026
6.2.11.3. Comparative market share analysis, 2018 & 2026

6.3. Asia-Pacific

6.3.1. Market size and forecast, by type, 2016-2026
6.3.2. Market size and forecast, by end-use, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026

6.3.5. China

6.3.5.1. Market size and forecast, by type, 2016-2026
6.3.5.2. Market size and forecast, by end-use, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026

6.3.6. Japan

6.3.6.1. Market size and forecast, by type, 2016-2026
6.3.6.2. Market size and forecast, by end-use, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026

6.3.7. India

6.3.7.1. Market size and forecast, by type, 2016-2026
6.3.7.2. Market size and forecast, by end-use, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026

6.3.8. South Korea

6.3.8.1. Market size and forecast, by type, 2016-2026
6.3.8.2. Market size and forecast, by end-use, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026

6.3.9. Australia

6.3.9.1. Market size and forecast, by type, 2016-2026
6.3.9.2. Market size and forecast, by end-use, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026

6.4. LAMEA

6.4.1. Market size and forecast, by type, 2016-2026
6.4.2. Market size and forecast, by end-use, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026

6.4.5. Latin America

6.4.5.1. Market size and forecast, by type, 2016-2026
6.4.5.2. Market size and forecast, by end-use, 2016-2026
6.4.5.3. Comparative market share analysis, 2018 & 2026

6.4.6. Middle East

6.4.6.1. Market size and forecast, by type, 2016-2026
6.4.6.2. Market size and forecast, by end-use, 2016-2026
6.4.6.3. Comparative market share analysis, 2018 & 2026

6.4.7. Africa

6.4.7.1. Market size and forecast, by type, 2016-2026
6.4.7.2. Market size and forecast, by end-use, 2016-2026
6.4.7.3. Comparative market share analysis, 2018 & 2026

6.4.8. Saudi Arabia

6.4.8.1. Market size and forecast, by type, 2016-2026
6.4.8.2. Market size and forecast, by end-use, 2016-2026
6.4.8.3. Comparative market share analysis, 2018 & 2026

7. Company profiles

7.1. BMC Medical Co., Ltd

7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Product portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis

7.2. Becton Dickinson (CareFusion Corporation)

7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Product portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis

7.3. Braebon Medical Corporation

7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Product portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis

7.4. Cadwell Laboratories Inc.

7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Product portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis

7.5. Compumedics Limited

7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Product portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis

7.6. Curative Medical Inc,

7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Product portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis

7.7. Fisher & Paykel Healthcare

7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Product portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis

7.8. GE Healthcare

7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Product portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis

7.9. ImThera Medical, Inc.

7.9.1. Business overview
7.9.2. Financial performance
7.9.3. Product portfolio
7.9.4. Recent strategic moves & developments
7.9.5. SWOT analysis

7.10. Invacare Corporation

7.10.1. Business overview
7.10.2. Financial performance
7.10.3. Product portfolio
7.10.4. Recent strategic moves & developments
7.10.5. SWOT analysis

Obstructive sleep apnea is a sleeping disorder where the breathing gets interrupted sporadically during sleep. This disorder occurs when the throat muscles shrink and block the air way when the person is asleep. of obstructive sleep apnea. Patients with neurological disorder are more prone to sleep apnea.

Snoring being the most noticeable sign of the disorder, excessive daytime sleepiness, non-refreshing sleep, chocking, and snoring, are the most common symptoms of the obstructive sleep apnea. It is being predicted that 9-26% of middle aged population are experiencing obstructive sleep apnea more than 15 times in an hour.

Market Growth Drivers

Rising cases of undiagnosed patient and rising awareness in the therapeutic obstructive sleep apnea is anticipated to boost the growth of therapeutic obstructive sleep apnea device market.

It has been predicted that approximately 80% of people who are facing obstructive sleep apnea are undiagnosed. If obstructive sleep apnea is left untreated, it may further cause various health issues such as diabetes, high blood pressure and sometimes it may even cause death. 

The rising sleep apnea cases is the key factor for the growth of therapeutic obstructive sleep apnea 

The growing cases of sleep apnea and the treatment followed by patient is very less, so spreading awareness among the patient about the sleep apnea devices can be considered as one of the main driving factor for therapeutic obstructive sleep apnea devices.

Obstacles

The biggest restraint in the therapeutic obstructive sleep apnea device market is that the patients are not tolerating the device. The device consists of a mask which causes discomfort to the patient as the pipe is attached to the mask and the mask is being completely covered which make the patient claustrophobic. 

The high cost of the sleep apnea devices can be considered as one of the biggest restraint for the growth of the therapeutic obstructive sleep apnea devices. Due to fear and high cost, customers lose interest in these devices which is anticipated to hamper the growth of therapeutic obstructive sleep apnea device market.

Recent Developments

Positive airway pressure therapy can treat sleep apnea. However, this treatment isn’t convenient for each and every patient. After many experiments, there are now many new and advanced devices have been introduced for better treatment of the disorder.

Hypoglossus Nerve Stimulation

Hypoglossus nerve stimulation (HNS) is a completely different approach for OSA treatment. This approach was approved by FDA in 2014. With HNS, a small device is surgically implanted in the chest. The device can be turned on and off by the patient which makes it more convenient. While you sleep, the device monitors your breathing and stimulates a nerve that keeps the upper airway open.

Expiratory Positive Airway Pressure (EPAP)

In the EPAP system, the disposable adhesive valves are placed over the nose when the patient is asleep. While inhaling, the valve opens and helps the airway remain clear. In time of exhaling, the airflow is directed into small channels, which creates pressure and keeps the airways free.

Leading companies operating in the therapeutic obstructive sleep apnea devices are BMC Medical Co., Ltd, Becton Dickinson (CareFusion Corporation). Braebon Medical Corporation, Cadwell Laboratories Inc., Compumedics Limited, Curative Medical Inc., Fisher & Paykel Healthcare, GE Healthcare, ImThera Medical, Inc., Invacare Corporation, and many more. 

According to a recent report by Research Dive, the global therapeutic obstructive sleep apnea device market forecasted to grow at a CAGR of 9.6% generating a revenue of $9,561.3 million by 2026 from $4661.6 million in 2018.

Purchase Options

Enquire To Buy

Personalize this research

  • Triangulate with your own data
  • Get Data as per your format and defination
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

RELATED TAGS

Therapeutic Obstructive Sleep Apnea Device

Customers Also Viewed